Amgen rolls out data for KRAS inhibitor combo study in colorectal cancer, hoping to move on from ugly early results

With the first win for its KRAS inhibitor sotorasib in hand, Amgen is pushing ahead with an aggressive clinical plan to capitalize on its first-to-market standing. The drugmaker thinks combinations — in-house or otherwise — could offer a path forward, and one early readout from that strategy is bearing fruit.


Click to view original post